Observes obinutuzumab with lenalidomide in people with returning follicular lymphoma
Observes obinutuzumab and lenalidomide treatment in adults with returning follicular lymphoma.
Plain-language title generated from the registry record
Registry title: Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
Key facts
- Where
- Tianjin, ChinaSee the site
Where in China
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Institute of Hematology & Blood Diseases Hospital, China
- Trial code
- NCT05846763
- Record updated
- 23 May 2023
- Original description
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in patients with R/R FL in a real-world setting in a Chinese population.Read full original descriptionShow less
Efficacy and Safety of Obinutuzumab in Combination With Lenalidomide in Patients With Relapsed and Refractory Follicular Lymphoma (R/R FL): A Prospective Observational Study
This study is planned to prospectively observe and verify the efficacy and safety of induction therapy with obinutuzumab in combination with lenalidomide followed by maintenance therapy with obinutuzumab and lenalidomide in patients with R/R FL in a real-world setting in a Chinese population.
Exclusion: Patients currently participating or planning to participate in any interventional clinical trial; Any other reason that, in the opinion of the investigator, makes the patient unsuitable for this study.
Patients must meet the following criteria for study entry::; Signed Informed Consent Form; Age ≥ 18 years at enrollment; At least one prior line of systemic (Stage III-IV) follicular lymphoma therapy; Relapsed or refractory to front-line anti-lymphoma therapy; refractory is defined as: tumor shrinkage of less than 50% or disease progression after 4 cycles of standard regimen chemotherapy; response to standard regimen chemotherapy, relapse within 24 months; 2 or more relapses, meeting one of the above criteria as refractory lymphoma; Conditional treatment with obinutuzumab in combination with lenalidomide.